BioNTech and DualityBio Form Global Strategic Partnership :

BioNTech receives exclusive licenses from DualityBio for two investigational antibody-drug conjugate assets (DB-1303 and DB-1311) directed against targets...

Related Keywords

China , Germany , Shanghai , John Zhu , Fosun Pharma , Ugur Sahin , Michael Horowicz , Pfizer , Genentech , Business Development , Drug Administration , Duality Biologics Suzhou Co , Roche Group , Duality Biologics , Mainland China , Hong Kong Special Administrative Region , Macau Special Administrative , Human Epidermal Growth Factor Receptor , Fast Track , Chief Executive Officer , Macau Special Administrative Region , Duality Immune Toxin Antibody Conjugates , New Technologies , Private Securities Litigation Reform Act , Annual Report , Antibody Drug Conjugate , Nasdaq Bntx , Biontech Se , Ntx , Dualitybio , Antibody Drug Conjugates , Dc , Ntik 246 Rper Wirkstoff Konjugate ,